Reduction of hair growth

Details Reduction of hair growth Reduction of hair growth

2005-05-31

2009-11-17

Kim, Jennifer M (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S169000, C514S171000, C514S559000, C424S070100, C424S073000

Reexamination Certificate

active

07618956

ABSTRACT:
Mammalian hair growth is reduced by applying an agonist of farnesoid X receptor.

REFERENCES:
patent: 3426137 (1969-02-01), Philpitt et al.
patent: 3878239 (1975-04-01), Hyashi et al.
patent: 4039669 (1977-08-01), Beyler et al.
patent: 4139638 (1979-02-01), Neri et al.
patent: 4161540 (1979-07-01), Neri et al.
patent: 4185099 (1980-01-01), Sorbini
patent: 4191775 (1980-03-01), Glen
patent: 4201873 (1980-05-01), Peterson
patent: 4203924 (1980-05-01), Nelson
patent: 4269831 (1981-05-01), Ferrari et al.
patent: 4370315 (1983-01-01), Greff et al.
patent: 4508714 (1985-04-01), Cecic et al.
patent: 4517175 (1985-05-01), Iwabuchi et al.
patent: 4562204 (1985-12-01), Wakatsuka et al.
patent: 4720489 (1988-01-01), Shander
patent: 4885289 (1989-12-01), Breuer et al.
patent: 4935231 (1990-06-01), Pigiet
patent: 5095007 (1992-03-01), Ahluwalia
patent: 5096911 (1992-03-01), Ahluwalia et al.
patent: 5132293 (1992-07-01), Shander et al.
patent: 5143925 (1992-09-01), Shander et al.
patent: 5183817 (1993-02-01), Bazzano
patent: 5189212 (1993-02-01), Ruenitz
patent: 5271942 (1993-12-01), Heverhagen
patent: 5300284 (1994-04-01), Wiechers et al.
patent: 5328686 (1994-07-01), Shander et al.
patent: 5362748 (1994-11-01), Schwen et al.
patent: 5364885 (1994-11-01), Ahluwalia et al.
patent: 5411991 (1995-05-01), Shander et al.
patent: 5444090 (1995-08-01), Ahluwalia
patent: 5455234 (1995-10-01), Ahluwalia et al.
patent: 5468476 (1995-11-01), Ahluwalia et al.
patent: 5474763 (1995-12-01), Shander et al.
patent: 5554608 (1996-09-01), Ahluwalia et al.
patent: 5645825 (1997-07-01), Hillebrand et al.
patent: 5648394 (1997-07-01), Boxall et al.
patent: 5652273 (1997-07-01), Henry et al.
patent: 5674477 (1997-10-01), Ahluwalia
patent: 5700835 (1997-12-01), Dean et al.
patent: 5728736 (1998-03-01), Shander et al.
patent: 5776442 (1998-07-01), Ahluwalia
patent: 5824665 (1998-10-01), Henry et al.
patent: 5824694 (1998-10-01), Kurtz et al.
patent: 5840752 (1998-11-01), Henry et al.
patent: 5866595 (1999-02-01), Pershadsingh et al.
patent: 5908867 (1999-06-01), Henry et al.
patent: 5939458 (1999-08-01), Henry et al.
patent: 5958946 (1999-09-01), Styczynski et al.
patent: 5962466 (1999-10-01), Styczynski et al.
patent: 5972944 (1999-10-01), Antonucci et al.
patent: 6020006 (2000-02-01), Styczynski et al.
patent: 6037326 (2000-03-01), Styczynski et al.
patent: 6060471 (2000-05-01), Styczynski et al.
patent: 6060515 (2000-05-01), Elias et al.
patent: 6071955 (2000-06-01), Elias et al.
patent: 6093748 (2000-07-01), Ahluwalia et al.
patent: 6121269 (2000-09-01), Henry et al.
patent: 6187814 (2001-02-01), Elias et al.
patent: 6218435 (2001-04-01), Henry et al.
patent: 6235737 (2001-05-01), Styczynski et al.
patent: 6239170 (2001-05-01), Ahluwalia et al.
patent: 6248751 (2001-06-01), Ahluwalia et al.
patent: 6284234 (2001-09-01), Niemiec et al.
patent: 6299865 (2001-10-01), Styczynski et al.
patent: 6369098 (2002-04-01), Pershadsingh et al.
patent: 6414017 (2002-07-01), Ahluwalia et al.
patent: 6419913 (2002-07-01), Niemiec et al.
patent: 6452032 (2002-09-01), Beard et al.
patent: 6613780 (2003-09-01), Yokota et al.
patent: 6743419 (2004-06-01), Shander et al.
patent: 6743822 (2004-06-01), Styczynski et al.
patent: 2002/0019338 (2002-02-01), Hebert
patent: 2002/0044953 (2002-04-01), Michelet et al.
patent: 2002/0045659 (2002-04-01), Michelet et al.
patent: 2002/0052414 (2002-05-01), Bernard et al.
patent: 2002/0052416 (2002-05-01), Michelet et al.
patent: 2003/0012755 (2003-01-01), Styczynski et al.
patent: 2003/0187042 (2003-10-01), Bauer et al.
patent: 2004/0176426 (2004-09-01), Houze et al.
patent: 2004/0180942 (2004-09-01), Martin et al.
patent: 2004/0192778 (2004-09-01), Jardien et al.
patent: 0 532 219 (1992-09-01), None
patent: 1 458 349 (1976-12-01), None
patent: 2005015408 (2005-01-01), None
patent: WO 92/10164 (1992-06-01), None
patent: WO 94/21216 (1994-09-01), None
patent: WO 98/02134 (1998-01-01), None
patent: WO 00/50002 (2000-08-01), None
patent: WO 01/54654 (2001-08-01), None
patent: WO 01/62237 (2001-08-01), None
patent: WO 02/072598 (2002-09-01), None
patent: WO 03/002756 (2003-01-01), None
patent: WO 03/015771 (2003-02-01), None
patent: WO 03/060078 (2003-07-01), None
patent: WO 03/076418 (2003-09-01), None
patent: WO 03/080803 (2003-10-01), None
patent: WO 2004/007521 (2004-01-01), None
patent: WO 2004/046162 (2004-06-01), None
patent: WO 2004/048349 (2004-06-01), None
Claudel et al. “The Farnesoid X Receptor: A Novel Drug Target?” Expert Opin. Investig. Drugs, (2004) 13(9): pp. 1135-1148.
Torra et al., “Identification of DRIP205 as a Coactivator for the Farnesoid X Receptor”, The Journal of Biology Chemistry, vol. 279, No. 35, pp. 36184-36191, Aug. 27, 2004.
Lew et al., “The Farnesoid X Receptor Controls Gene Expression in a Ligand- and Promoter-Selection Fashion”, The Journal of Biological Chemistry, vol. 279, No. 10, pp. 8856-8861, Mar. 5, 2004.
Zhang et al., “Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α (PGC-1α) Regulates Triglyceride Metabolism by Activation of the Nuclear Receptor FXR”, Genes & Development 18:157-169, 2004.
Houck et al., “T0901317 is a Dual LXR/FXR Agonist”, Molecular Genes and Metabolism, 83, pp. 184-187, 2004.
Pellicciari et al., “Bile Acid Derivatives as Ligands of the Farnesoid X Receptor, Synthesis, Evaluation, and Structure-Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid”, J. Med. Chem., 47, pp. 4559-4569, 2004.
Lu et al., “Orphan Nuclear Receptors as eLiXiRs and FiXeRs of Sterol Metabolism”, The Journal of Biological Chemistry, vol. 276, No. 41, pp. 37734-37738, Oct. 12, 2001.
Niesor et al., “The Nucelar Receptors FXR and LXRα: Potential Targets for the Development of Drugs Affecting Lipid Metabolism and Neoplastic Diseases” Current Pharmaceutical Design, No. 7, pp. 231-259, 2001.
Maloney et al., “Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR”, Journal of Medicinal Chemistry, vol. 43, No. 16, pp. 2971-2974, Aug. 10, 2000.
Hanley et al., “Fetal Epidermal Differentiation and Barrier Development In Vivo is Accelerated by Nuclear Hormone Receptor Activators”, The Society for Investigative Dermatology, Inc., vol. 113, No. 5, pp. 788-795, Nov. 1999.
Niesor et al., “Synthetic Farnesoid X Receptor (FXR) Agonists: A New Class of Cholesterol Synthesis Inhibitors and Antiproliferative Drugs”, Drugs of the Future, 24(4), pp. 431-438, 1999.
Hoffmann et al., “Interleukin-1 β-Induced Inhibition of Hair Growth In Vitro Is Mediated by Cyclic AMP”,The Journal of Investigative Dermatology, vol. 108, pp. 40-42, 1997.
Hashizume et al., “Hair cycle-dependent expression of heat shock proteins in hair follicle epithelium”, Int. J. of Dermatol., vol. 36, pp. 587-592, 1997.
Messenger, Andrew G., “The Control of Hair Growth: An Overview”,The Journal of Investigative Dermatology, vol. 101, No. 1, pp. 4s-9s, 1993.
Weinberg et al., “Reconstitution of Hair Follicle Development In Vitro: Determination of Follicle Formation, Hair Growth, and Hair Quality by Dermal Cells”,The Journal of Investigative Dermatology, vol. 100, pp. 229-236, 1993.
Ebling, F. John G., “The Biology of Hair”,Dermatologic Clinics, vol. 5, No. 3, pp. 467-481, 1987.
Hattori et al., “Biochemical Analysis of Hair Growth From the Aspects of Aging and Enzyme Activities”,The Journal of Dermatology, vol. 10, pp. 45-54, 1983.
Sato, Yoshio, “The Hair Cycle and Its Control Mechanism”, pp. 3-13, 1976.
Adachi et al., “Human Hair Follicles: Metabolism and Control Mechanisms”,Journal of the Society of Cosmetic Chemists, vol. 21, No. 13, pp. 901-924, 1970.
Narisawa et al., “Inhibitory Effects of Ursodeoxycholic Acid on N-Methyl-nitrosourea-Induced Colon Carcinogenesis and Colonic Mucosal Telomerase Activity in F344 Rats”, J. Exp. Clin. Cancer Res

Affiliated with

Also associated with

Rating

Reduction of hair growth does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reduction of hair growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of hair growth will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4109437